Navigation Links
Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Date:11/9/2012

SUNNYVALE, Calif., Nov. 9, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS) is issuing corrections to a press release dated November 7 regarding data from a study into MANF, funded by The Michael J. Fox Foundation (MJFF). 

To clarify remarks in the original release, MJFF does not agree with Amarantus' statements that, to-date, reported behavioural pre-clinical data were positive, and that histology data confirm re-innervation of the striatum due to MANF delivery. MJFF reserves any view on the histology results until the final data are available.  In addition, MJFF is not considering additional funding to Amarantus at this time. Amarantus has announced the final data will be available in December.

MJFF continues to invest in promising neurotrophic factor approaches, and will apply takeaways from this study to future initiatives.  The Foundation still believes that MANF is a potentially promising trophic factor. 

A link to the original release is below.  

http://www.prnewswire.com/news-releases/amarantus-biosciences-updates-shareholders-on-timing-of-michael-j-fox-foundation-grant-data-release-177625521.html

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
2. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
5. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
6. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
7. Neurocrine Biosciences Reports Third Quarter 2012 Results
8. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
9. AMRI Announces Strategic Contract with Knopp Biosciences
10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
11. Neurocrine Biosciences Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Inc. (OTC Bulletin Board: CSBR ), a ... and tumor specific data to enhance the value of ... joined the management team as the Chief Executive Officer ... Dr. Ronnie Morris will join the management team as ...
... Oct. 28 Q3 2010 Change on a reported ... 9 months 2010Change on a reported ... sales , €7,821m+5.7% , -1.7% , €22,989m+4.8% , ... €7,377m+8.7% , +6.0%Business EPS(1)€1.89+8.6%-2.3%€5.65+8.7%+6.0% In order to facilitate an understanding ...
Cached Biology Technology:Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 2Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 3Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 4Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 5Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 6Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 7Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 8Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 9Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 10Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 11Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 12Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 13Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 14Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 15Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 16Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 17Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 18Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 19Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 20Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 21Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 22Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 23Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 24Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 25Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 26Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 27Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 28Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 29Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 30Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 31Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 32Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 33Champions Biotechnology Reports Additions to its Management Team 2Champions Biotechnology Reports Additions to its Management Team 3Champions Biotechnology Reports Additions to its Management Team 4
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 4, 2010 -- Supercomputer simulations at the Department of Energy,s ... acids could have contributed to the origins of life. ... directs ORNL,s Center for Molecular Biophysics and holds a Governor,s ... probe an organic chemical reaction that may have been important ...
... Rockville, MD, USA (October 4, 2010) The ... receipt of a grant from the United States Food ... immunological biomarkers for TB vaccine development. The FDA grant, ... researchers from the United States, the United Kingdom and ...
... Ben Major, PhD, assistant professor of cell and developmental ... of Health Director,s New Innovator Awards, one of the ... will fund his work to address a significant medical ... functionally contribute to specific cellular and disease processes such ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2Aeras-led research consortium receives FDA support 2UNC scientist receives NIH director's New Innovator Award 2
... to the Salmonella Common Structural Antigens (CSA) ... serum pool of goats immunized with different ... broadly reactive to Salmonella and recognizes all ... excellent specificity for Group B and D ...
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... products into 1:, , A multi-tube homogenizer ... , ,The FastPrep System consists of ... Matrix and Isolation Kits. Samples are homogenized ... the use of metal probes and shearing ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: